Reviva Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 21:30
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.06.

EBIT: As of FY2025 Q3, the actual value is USD -4.086 M.

Segment Revenue

Reviva Pharmaceuticals Holdings, Inc. did not generate any revenues from the sale of products during the reporting period.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was - $4,010,773, compared to - $8,365,798 for the same period in 2024.
  • Total Operating Expenses: For the three months ended September 30, 2025, total operating expenses were $4,029,841, compared to $8,462,534 for the same period in 2024.
  • Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $2,131,444, compared to $6,858,285 for the same period in 2024.
  • General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $1,898,397, compared to $1,604,249 for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $18,796,432, compared to - $24,443,419 for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $18,503,360, compared to $6,634,780 for the same period in 2024.

Unique Metrics

  • Working Capital Surplus: As of September 30, 2025, the company had a working capital surplus of approximately $3.8 million.

Future Outlook and Strategy

  • Core Business Focus: The company plans to complete the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia, with a potential NDA submission targeted for Q2-2026, subject to FDA approval.
  • Non-Core Business: The company may continue the clinical development of brilaroxazine for other indications such as bipolar disorder, major depressive disorder, and respiratory conditions, subject to additional financing.
  • Priority: The company emphasizes the need for additional fundraising activities to continue its development efforts and operations, with a focus on securing public or private equity or debt financings.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.